argenx SE (NASDAQ:ARGX) Stock Holdings Decreased by Raymond James & Associates

Raymond James & Associates cut its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 2.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,803 shares of the company's stock after selling 1,308 shares during the quarter. Raymond James & Associates owned about 0.09% of argenx worth $29,166,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Blue Trust Inc. raised its position in shares of argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company's stock worth $201,000 after acquiring an additional 298 shares during the period. Aaron Wealth Advisors LLC acquired a new stake in shares of argenx during the 3rd quarter worth approximately $241,000. Creative Planning increased its holdings in shares of argenx by 54.1% during the 3rd quarter. Creative Planning now owns 5,437 shares of the company's stock worth $2,947,000 after buying an additional 1,909 shares during the last quarter. Ritholtz Wealth Management acquired a new stake in shares of argenx during the 3rd quarter worth approximately $262,000. Finally, Perpetual Ltd acquired a new stake in shares of argenx during the 3rd quarter worth approximately $76,314,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

ARGX traded down $6.77 during trading hours on Thursday, reaching $551.15. 99,779 shares of the stock traded hands, compared to its average volume of 308,607. The firm's fifty day simple moving average is $534.21 and its two-hundred day simple moving average is $458.10. The company has a market cap of $32.76 billion, a price-to-earnings ratio of -97.38 and a beta of 0.63. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $571.97.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The firm had revenue of $489.43 million for the quarter, compared to the consensus estimate of $436.66 million. During the same period in the prior year, the firm posted ($1.69) EPS. On average, research analysts predict that argenx SE will post -0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Robert W. Baird lifted their target price on shares of argenx from $490.00 to $515.00 and gave the company an "outperform" rating in a report on Monday, July 29th. Citigroup boosted their price target on shares of argenx from $512.00 to $635.00 and gave the company a "buy" rating in a research report on Thursday, October 17th. Truist Financial boosted their price target on shares of argenx from $480.00 to $540.00 and gave the company a "buy" rating in a research report on Monday, July 22nd. JPMorgan Chase & Co. lifted their price objective on shares of argenx from $500.00 to $640.00 and gave the company an "overweight" rating in a research note on Friday, August 23rd. Finally, Oppenheimer upgraded shares of argenx from a "market perform" rating to an "outperform" rating and set a $546.00 price objective on the stock in a research note on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $550.44.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.